Moderna Stock Tanks on Review, arguing that Covid vaccine booster might not be needed

Text size

Modern

actions, as well as actions of the manufacturers of Covid vaccines

BioNTech

and

Novavax,

slipped after a Lancet article suggested that a recall would not be necessary for most people.

In morning trading, Moderna (MRNA) stock fell 5.8%, while BioNTech (BNTX) fell 5.6% and Novavax (NVAX) fell 2.4%.

Pfizer

(PFE), partner of BioNTech, had slipped by 2%. The

S&P 500

was up 0.1%.

The Lancet article was a review of clinical trial data, as well as real-world efficacy. The authors, who included the FDA’s Marion Gruber and Philip Krause, argue that there is no evidence that vaccines lose their ability to protect against “serious disease, even when there appears to be a decline over time. time of vaccine effectiveness against symptomatic disease ”.

The debate over whether to use booster shots in the United States is ongoing, even as Israel begins to discuss the possibility of a fourth injection. Continuing vaccinations would generate longer-term revenue streams for vaccine manufacturers.

Write to Ben Levisohn at [email protected]